全基因组CRISPR/Cas9筛选鉴定急性淋巴细胞白血病中帕比司他敏感性的决定因素
该研究采用全基因组CRISPR/Cas9筛选,发现线粒体活性是急性淋巴细胞白血病(ALL)中帕比司他耐药的关键驱动因素;SIRT1异位表达可激活线粒体活性,并通过激活线粒体相关凋亡通路使ALL对帕比司他敏感;SIRT1转录水平与多种肿瘤类型中帕比司他敏感性显著相关,可能成为帕比司他反应的潜在生物标志物。
要点
- 全基因组CRISPR/Cas9筛选鉴定线粒体活性为ALL中帕比司他耐药驱动因素。
- SIRT1异位表达激活线粒体活性,经线粒体相关凋亡通路增敏ALL对帕比司他。
- SIRT1转录水平与多种肿瘤类型帕比司他敏感性显著相关,或为潜在生物标志物。
核心结论
- 研究数据提示,癌细胞中SIRT1表达较高的患者可能从帕比司他治疗中获益。
- 研究支持联合使用SIRT1或线粒体激活剂以克服帕比司他耐药。
研究设计与样本
- 研究采用全基因组CRISPR/Cas9筛选技术。
- 研究涉及急性淋巴细胞白血病(ALL)细胞模型。
主要发现
- 全基因组CRISPR/Cas9筛选鉴定线粒体活性为ALL中帕比司他耐药驱动因素。
- SIRT1异位表达激活线粒体活性,并通过激活线粒体相关凋亡通路使ALL对帕比司他敏感。
- SIRT1转录水平与多种肿瘤类型中帕比司他敏感性显著相关,可能成为帕比司他反应潜在生物标志物。
关键数值与推荐
- 帕比司他为泛组蛋白去乙酰化酶抑制剂,已获美国食品药品监督管理局批准用于治疗多发性骨髓瘤。
- 帕比司他在急性淋巴细胞白血病中显示出有前景的抗白血病效应。
临床怎么用
- 原文未据此给出具体临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Epigenetic alterations, including histone acetylation, contribute to the malignant transformation of hematopoietic cells and disease progression, as well as the emergence of chemotherapy resistance. Targeting histone acetylation provides new strategies for the treatment of cancers. As a pan-histone deacetylase inhibitor, panobinostat has been approved by the US Food and Drug Administration for the treatment of multiple myeloma and has shown promising antileukemia effects in acute lymphoblastic leukemia (ALL). However, the underlying drug resistance mechanism in ALL remains largely unknown. Using genome-wide Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated (Cas)9 (CRISPR/Cas9) screening, we identified mitochondrial activity as the driver of panobinostat resistance in ALL. Mechanistically, ectopic SIRT1 expression activated mitochondrial activity and sensitized ALL to panobinostat through activating mitochondria-related apoptosis pathway. Meanwhile, the transcription level of SIRT1 was significantly associated with panobinostat sensitivity across diverse tumor types and thus could be a potential biomarker of panobinostat response in cancers. Our data suggest that patients with higher SIRT1 expression in cancer cells might benefit from panobinostat treatment, supporting the implementation of combinatorial therapy with SIRT1 or mitochondrial activators to overcome panobinostat resistance.
引用
- Jiang C, Qian M, Gocho Y, et al. Genome-wide CRISPR/Cas9 screening identifies determinant of panobinostat sensitivity in acute lymphoblastic leukemia. Blood Adv. 2022. PMID: 35192680. doi:10.1182/bloodadvances.2021006152
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。